Hurvitz Brain Sciences Program
SRI programs
Affiliate scientist
Sunnybrook Health Sciences Centre
2075 Bayview Ave., Room FG 19
Toronto, ON
M4N 3M5
Administrative Assistant: Kathy Ostaff
Phone: 416-480-5013
Email: kathy.ostaff@sunnybrook.ca
Education:
- MD, 1983, University of Toronto, Canada
- FRCP(C), 1988, psychiatry, U of T, Canada
Appointments and Affiliations:
- Affiliate scientist, Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute
- Head, division of geriatric psychiatry, department of psychiatry, U of T (1995–2005)
- Professor, department of psychiatry, faculty of medicine, U of T
Research Foci:
- Clinical neuropharmacology
- Geriatric psychiatry
Research Summary:
Dr. Herrmann's major contributions to neuroscience research are in the areas of the clinical pharmacology of dementia (treatment of behavioural disturbances and cognition), post-stroke depression and the pharmacotherapy of late-life affective disorders. He has published numerous studies on the pharmacotherapy of behavioural disturbances in dementia that involve the use of novel agents, which attempt to determine the underlying neurobiology of these disorders. He has also participated in studies of post-stroke depression examining its neuroimaging and biological correlates. In addition, he has published studies, reviews and guidelines on the management of depression and bipolar illness in late-life, and has participated in psychopharmacology projects on drug-drug interactions and adverse events.
Selected Publications:
See current publications list at PubMed.
- Mohammad D, Chan P, Bradley J, Lanctôt KL, Herrmann N. Acetylcholinesterase inhibitors for treating dementia symptoms: a safety evaluation. Expert Opinion on Drug Safety. 2017. doi: 10.1080/14740338.2017.1351540.
- Lai KSP, Liu CS, Rau A, Lanctôt KL, Köhler CA, Pakosh M, Carvalho AF, Herrmann N. Peripheral inflammatory markers in Alzheimer's disease: a systematic review and meta-analysis of 175 studies. J Neurol Neurosurg Psychiatry. 2017 Aug 9. PII: jnnp-2017-316201. doi: 10.1136/jnnp-2017-316201.
- Herrmann N, O’Regan J, Ruthirakuhan M, Kiss A, Eryavec G, Williams E, Lanctôt KL. A randomized placebo-controlled discontinuation study of cholinesterase inhibitors in moderate to severe Alzheimer’s disease patients. J Am Med Dir Assoc. 2016 Feb;17:142–7.
- Herrmann N, Hogan D, Lanctôt KL. Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the diagnosis and treatment of dementia 2012. Alzheimers Res Ther. 2013 Jul 8;5(Suppl 1):S5.
- Herrmann N, Gauthier S, Boneva N, Lemming OM. A randomized, double-blind placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease. Int Psychogeriatr. 2013 Jun;25(6):919–27.
Related News and Stories:
- SRI scientists top the national average in successful CIHR project grants: Over a dozen projects approved (June 2, 2017)
- Dementia and driving: when it’s time to hang up the keys (Huffington Post, July 12, 2016)
- When to call it quits: Study examines health effects of stopping drug treatments in elderly patients with Alzheimer’s disease (Jan. 29, 2016)
- Take three sardines and call me in the morning: Could fish oil help treat cognitive impairment? (SRI Magazine, 2013)
- Symptoms of Alzheimer's significantly improved with new treatment (The Globe and Mail, April 2, 2013)
- Sunnybrook researchers studying emotional issues in Alzheimer's patients (The Globe and Mail, Jan. 13, 2012)
- Boom, baby boom!: Aging, dementia and the cost to family caregivers (SRI Magazine, 2011)
- When should doctors take the keys from older drivers? (Toronto Star, March 20, 2010)
- Severe Alzheimer's management recommendations: Condition requires more frequent monitoring by health professionals, says new report (Dec. 1, 2008)
- Dementia patients on psychotropic medications at high risk for collisions: Symptoms or prescription of meds should prompt physicians to evaluate effect on road safety (Oct. 8, 2008)
- Caring enough: Two SRI neuroscientists investigate the link between Alzheimer’s disease and apathy (Feb. 19, 2008)
- The skeptics: Two SRI docs question new findings on a drug (Oct. 16, 2006)
Related Links:
